Skip to main content

CORRECTION article

Front. Oncol., 13 December 2022
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1107271

Corrigendum: Identification and management of aggressive meningiomas

This article is a correction to:

  1. Editorial: Meningioma: From Basic Research to Clinical Translational Study

    1. Read original article
Bhuvic PatelBhuvic Patel1Rupen DesaiRupen Desai1Sangami PugazenthiSangami Pugazenthi1Omar H. Butt,Omar H. Butt2,3Jiayi Huang,Jiayi Huang3,4Albert H. Kim,*Albert H. Kim1,3*
  • 1Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, United States
  • 2Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States
  • 3The Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States
  • 4Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States

A Corrigendum on
Identification and management of aggressive meningiomas

By Patel B, Desai R, Pugazenthi S, Butt OH, Huang J and Kim AH (2022) 12:851758. doi: 10.3389/fonc.2022.851758

Error in Figure

In the published article, there was an error in Figure 1. All locations in the figure that mention “TRAF4” are incorrect and should be changed to “TRAF7”. The corrected Figure 1 and its caption (unchanged) appear below.

FIGURE 1
www.frontiersin.org

Figure 1 Common intracranial locations of meningiomas highlighted in this review with associated DNA driver mutations or chromosomal loss (6, 14, 23, 24). Locations correlated to a generalized scale ranging from less (green) to more (red) complicated to resect and manage. Meningioma locations not pictured include clinoid, foramen magnum, cavernous sinus, suprasellar, and tentorial.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: meningioma, CNS tumors, chemotherapy, radiation therapy, immunotherapy, skull base surgery

Citation: Patel B, Desai R, Pugazenthi S, Butt OH, Huang J and Kim AH (2022) Corrigendum: Identification and management of aggressive meningiomas. Front. Oncol. 12:1107271. doi: 10.3389/fonc.2022.1107271

Received: 24 November 2022; Accepted: 28 November 2022;
Published: 13 December 2022.

Edited and Reviewed by:

Hailiang Tang, Fudan University, China

Copyright © 2022 Patel, Desai, Pugazenthi, Butt, Huang and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Albert H. Kim, alberthkim@wustl.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.